Early initiation of SGLT2 inhibitors within guideline-directed medical therapy and outcomes in newly diagnosed heart failure patients.

ABSTRACT:

Introduction

Heart failure (HF) is a major cause of hospitalization and mortality. Early initiation of guideline-directed medical therapy (GDMT) improves outcomes in heart failure with reduced ejection fraction (HFrEF). This study assesses the impact of starting GDMT with an SGLT2i in newly diagnosed HFrEF patients.

Materials and methods

The XXXX1 multicenter prospective registry enrolled consecutive newly diagnosed HFrEF patients between October 2021 and March 2022 to evaluate the influence of medical treatment schedules in newly diagnosed HFrEF. In this substudy, patients were grouped by initial GDMT with or without an SGLT2i. Over six months, clinical variables, echocardiographic and laboratory parameters, and clinical events (hospitalizations, emergency visits) were coll

SUBMITTER: Esteban-Fernandez A 

PROVIDER: S-EPMC12750671 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature